Endocrinology Today—March 17, 2026

This week’s Endocrinology update highlights clinical data readouts, device launches, automation advances, and continued investment across diabetes and fertility care.

In Today’s Newsletter

Dive deeper

💊 Lexicon highlights sotagliflozin type 1 diabetes analysis [1] [US • 12 Mar 2026]

https://www.thepharmaletter.com/pharma-news/lexicon-reports-new-analysis-of-sotagliflozin-data-in-type-1-diabetes
Context: Lexicon Pharmaceuticals pooled two identically designed 52-week placebo-controlled trials of sotagliflozin 200 mg and 400 mg added to optimized insulin therapy.
Key point: The company said a post hoc analysis suggested improved glycaemic control measures after one year in people with type 1 diabetes and normal or mildly reduced kidney function.
Implication: May influence prescriber choice and payer reviews pending full data.

📱 Zydus launches Diasens and GlucoLive CGM in India [2] [India • 12 Mar 2026]

https://www.expresshealthcare.in/amp/news/zydus-lifesciences-launches-diasens-and-glucolive-cgm-devices-for-diabetes-monitoring/453008/
https://www.expresspharma.in/amp/zydus-expands-companion-diagnostics-portfolio-with-launch-of-ai-powered-continuous-glucose-monitor/
Context: Zydus Lifesciences partnered with Digicare Health Solutions (TatvaCare) to connect the devices with the GoodFlip digital care platform.
Key point: Diasens and GlucoLive are AI-enabled CGM devices that stream readings every three minutes without manual scanning and support patient, caregiver and clinician connectivity.
Implication: Could streamline initiation and adherence via remote prescribing and logistics.

🧠 Dexcom broadens CGM evidence at ATTD 2026 [3] [11 Mar 2026]

https://www.biospace.com/press-releases/dexcom-showcases-breakthrough-outcomes-for-people-with-type-2-diabetes-and-product-roadmap-at-attd-2026
Context: Dexcom highlighted registry, claims and feasibility data, plus education and product roadmap updates presented at ATTD 2026 in Barcelona.
Key point: The company said Dexcom G7 use in non-insulin-treated type 2 diabetes was associated with improved A1C and weight outcomes, and CGM initiation in type 1 diabetes was associated with fewer DKA-related hospitalizations and ER visits.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

📊 Abbott reports FreeDM2 Libre gains in basal insulin-treated type 2 diabetes [4] [US • 12 Mar 2026]

https://www.prnewswire.com/news-releases/landmark-study-shows-libre-technology-helps-people-with-type-2-diabetes-on-basal-insulin-improve-glucose-management-302711766.html
Context: The U.K. FreeDM2 randomized controlled trial enrolled 303 participants across 24 sites; a separate Italian interventional study followed 88 adults in routine practice.
Key point: Abbott said FreeStyle Libre use led to a 0.6% greater HbA1c reduction and 2.5 more hours per day in range versus fingersticks at four months in basal insulin-treated type 2 diabetes.
Implication: May influence prescriber choice and payer reviews pending full data.

🧪 Biomea shares 52-week icovamenib follow-up in type 2 diabetes [5] [US • 14 Mar 2026]

https://www.bakersfield.com/ap/news/biomea-fusion-presents-phase-ii-covalent-111-data-in-type-2-diabetes-at-the-19th/article_dccdf12b-ad71-5c4c-925d-4631d4601e01.html
Context: Biomea Fusion presented 52-week follow-up from the Phase II COVALENT-111 study of icovamenib at ATTD 2026.
Key point: The company highlighted positive efficacy, safety and tolerability follow-up data at Week 52 and said it had identified dose and target patient subgroups for two new Phase II studies.
Implication: May influence prescriber choice and payer reviews pending full data.

🌸 Nexpring backs May Health in PCOS-related infertility [6] [US • 10 Mar 2026]

https://www.businesswire.com/news/home/20260310615805/en/Nexpring-Health-Invests-in-May-Health-to-Advance-a-Novel-Technology-to-Treat-PCOS-Related-Infertility
Context: Nexpring Health joined May Health’s €10 million financing round; May Health’s Anavi System received CE Mark under EU MDR in Oct 2025 and its U.S. REBALANCE IDE study is ongoing.
Key point: The investment supports development of a one-time, office-based device approach intended to restore ovulation in women with PCOS-related infertility.
Implication: Signals pipeline investment and modality expansion.

🤖 Insulet advances fully closed-loop Omnipod for type 2 diabetes [7] [11 Mar 2026]

https://www.drugdeliverybusiness.com/insulet-outcomes-fully-closed-loop-insulin-pump-study/
Context: EVOLUTION 2 was a multicenter feasibility study in 24 adults in New Zealand, evaluating algorithm versions for a fully closed-loop Omnipod system.
Key point: Insulet reported 68% average time in range with the final algorithm, a 24% improvement over standard injection therapy, with no severe hypoglycaemia or DKA events observed.
Implication: May influence prescriber choice and payer reviews pending full data.

🧬 NewcelX and Eledon team up on type 1 diabetes cell therapy [8] [Switzerland • 09 Mar 2026]

https://www.prnewswire.com/news-releases/newcelx-announces-strategic-collaboration-with-eledon-pharmaceuticals-to-advance-ncel-101-program-for-type-1-diabetes-302708071.html
Context: The collaboration combines NewcelX’s stem-cell-derived islet program NCEL-101 with Eledon Pharmaceuticals’ investigational anti-CD40L antibody tegoprubart.
Key point: The companies said the research agreement is intended to support durable graft survival, immune protection and a clearer development path for type 1 diabetes cell replacement.
Implication: Signals pipeline investment and modality expansion.

Why It Matters

CGM vendors, including Zydus, Dexcom and Abbott, are pushing beyond traditional insulin-intensive populations into broader type 2 diabetes use cases [2][3][4].
ATTD 2026 was a major launch point for diabetes device, data and drug updates, with multiple companies using the meeting to frame access and adoption narratives [1][3][4][5][7].
Insulet’s and Dexcom’s updates show continued movement toward more automation and simpler clinical workflows in diabetes management [3][7].
Lexicon and Biomea added fresh drug-development signals in type 1 and type 2 diabetes, though both summaries rely on company-reported or conference-stage data [1][5].
Deal activity in PCOS-related infertility and type 1 diabetes cell therapy suggests investor interest remains active in adjacent endocrine and metabolic platforms [6][8].

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🎬 Watch on YouTube. Subscribe and never miss a video.

🧰 See our full range of services. Discover how we can help you.

📚 View the full Endocrinology archive on our research hub page.

FAQ

What did Lexicon say about sotagliflozin in type 1 diabetes?

Lexicon said a post hoc pooled analysis from two 52-week placebo-controlled trials suggested sotagliflozin improved multiple glycaemic control measures after one year in people with type 1 diabetes and preserved or mildly reduced kidney function [1].

What is new about Zydus’s Diasens and GlucoLive devices?

Zydus said the CGM devices automatically stream glucose readings every three minutes, use AI-based analytics, and connect with TatvaCare’s GoodFlip platform for coaching, consultations and remote monitoring in India [2].

What were the main Abbott FreeDM2 findings?

Abbott reported that FreeStyle Libre users in the U.K. FreeDM2 randomized trial achieved a 0.6% greater HbA1c reduction and 2.5 more hours per day in range than fingerstick monitoring at four months [4].

How is Dexcom positioning CGM for type 2 diabetes?

Dexcom used ATTD 2026 to highlight registry data in non-insulin-treated type 2 diabetes, feasibility data for basal insulin optimization, and broader education efforts to support CGM uptake across care settings [3].

What did Insulet report from EVOLUTION 2?

Insulet said its fully closed-loop Omnipod feasibility study reached 68% average time in range with the final algorithm and observed no severe hypoglycaemia or DKA events in the study population [7].

Why does the NewcelX and Eledon collaboration matter?

The agreement combines stem-cell-derived islets with targeted immune modulation, aiming to improve durability and graft protection for NCEL-101 in type 1 diabetes development [8].

Entities / Keywords

Lexicon Pharmaceuticals, sotagliflozin, type 1 diabetes, kidney function, Zydus Lifesciences, Diasens, GlucoLive, continuous glucose monitor, CGM, TatvaCare, GoodFlip, Dexcom, Dexcom G7, Dexcom Smart Basal, Dexcom Academy, Abbott, FreeStyle Libre, FreeDM2, basal insulin, Biomea Fusion, icovamenib, COVALENT-111, Nexpring Health, May Health, Anavi System, PCOS-related infertility, REBALANCE, Insulet, Omnipod 5, EVOLUTION 2, fully closed-loop insulin delivery, NewcelX, NCEL-101, Eledon Pharmaceuticals, tegoprubart, anti-CD40L, stem-cell-derived islets